RGNX
Regenxbio Inc
NASDAQ · Biotechnology
$10.33
+0.07 (+0.68%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 85.20M | 151.69M | 90.45M | 81.92M | 77.44M |
| Net Income | -232,213,149 | -372,070,204 | 17.14M | 13.19M | 16.19M |
| EPS | — | — | — | — | — |
| Profit Margin | -272.5% | -258.9% | 19.0% | 16.1% | 20.9% |
| Rev Growth | -43.8% | -43.8% | +14.5% | +8.8% | +5.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 112.30M | 100.32M | 116.10M |
| Total Equity | — | — | 255.49M | 233.09M | 229.51M |
| D/E Ratio | — | — | 0.44 | 0.43 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -221,096,320 | -373,938,942 | 30.51M | 28.49M | 26.62M |
| Free Cash Flow | — | — | 17.02M | 20.59M | 19.17M |